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We studied the roles of autologous (A) and allogeneic (allo) stem cell transplantation (SCT) in the treatment of
134 patients with T cell lymphoma (TCL) at our center. For frontline SCT, 58 patients were studied. The 4-year
overall survival (OS) rates for ASCT (n ¼ 47; median age, 49 years) and alloSCT (n ¼ 11; median age, 55 years)
groups were 76% and 54%, respectively (P > .05). The 4-year OS rates for ﬁrst complete remission (CR1)
patients were 84% and 83%, respectively. For SCT for relapsed disease, 76 patients were studied (41 with ASCT
and 35 with alloSCT). The 4-year OS rates were 50% and 36% for ASCT and alloSCT patients with chemo-
sensitive disease, respectively (P > .05). Those who were in CR2 and CR3 had 4-year OS rates of 59% and 53%,
respectively. Similar results were also observed in patients with refractory disease (29% and 35%, respec-
tively). These data suggest that a pre-SCT CR is associated with improved outcomes in TCL patients after SCT.
Considering the 84% 4-year OS rates in CR1 patients and the unpredictable responses in patients with
relapsed disease, we favor the use of ASCT as consolidation therapy after CR1. AlloSCT did not result in a
superior outcome compared with ASCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
T cell lymphomas (TCLs) are a heterogeneous group of
neoplasms that represent 15% of non-Hodgkin lymphomas
[1,2]. TLCs are more resistant to conventional chemotherapy
than are B cell lymphomas, and patients have an inferior
outcome, with the exception of patients with anaplastic
lymphoma kinase (ALK)-positive anaplastic large-cell lym-
phoma (ALCL) [3]. Treatment with newly developed agents
results in improved responses [4-6], but relapse is common,
especially in patients with advanced and recurrent disease.
High-dose chemotherapy, followed by autologous (A) [7-12]
or allogeneic (allo) [13-17] hematopoietic stem cell trans-
plantation (SCT), is often considered for patients with TCL;dgments on page 858
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ty for Blood and Marrow Transplantation.however, which approach is more effective is not clear. The
results are further confounded by changes in lymphoma
classiﬁcation schemes over the past 2 decades [18] and the
development of prognostic markers and scores for TCL pa-
tients [19,20].
The results of several phase II trials have suggested that
alloSCT leads to improved outcomes [13-16]. However, the
rarity and diversity of TCLs and the evolving classiﬁcation
schemes have made it challenging to conduct randomized
controlled studies. To determine the role of SCT in the
management of TCL, we analyzed transplantation results at
our cancer center. We compared the results of ASCT and
alloSCT with patient and disease characteristics, such as
remission status, and histological disease type.METHODS
Patient Population and Synopsis of Transplantation Strategy
This study included all patients with TCL who had been treated in
sequential phase II ASCT or alloSCT protocols at The University of Texas MD
Anderson Cancer Center (Houston, TX) between 1990 and 2009. The
Table 1
Frontline SCT for TCL: Patient and Disease Characteristics
Characteristic ASCT AlloSCT
No. of patients 47 11
Median age, yr (range) 49 (18-75) 55 (47-62)
>60 yr, n (%) 9 (19) 3 (27)
Male sex, n (%) 32 (68) 8 (73)
Histological type, n (%)
N-TCL 38 (81) 8 (73)
PTCL-NOS 24 (51) 4 (36)
ALK-negative ALCL 4 (9) 1 (9)
AITL 10 (21) 3 (27)
EN-TCL 9 (19) 3 (27)
NK-TCL 2 (4) 1 (9)
HSTCL 6 (13) 2 (18)
SPTCL 1 (2) 0 (0)
CR1/PIF CR 38 (81) 6 (55)
PIF/PR 9 (19) 5 (45)
Transplantation before year 2000, n (%) 7 (15) 1 (9)
IPI score > 1 at SCT, n (%) 5 (11) 4 (36)
Elevated LDH at SCT, n (%) 14 (30) 6 (55)
Marrow þ at SCT, n (%) 2 (4) 3 (27)
Median prior chemotherapy regimens 1 2
Related/unrelated donor NA 8/3
N-TCL indicates nodal TCL; EN-TCL, extranodal TCL; NK-TCL, natural killer
TCL; HSTCL, hepatosplenic TCL; SPTCL, subcutaneous panniculitis-like TCL;
IPI, International Prognostic Index; LDH, lactate dehydrogenase.
Table 2
SCT for Relapsed TCL: Patient and Disease Characteristics
Characteristic ASCT AlloSCT
No. of patients 41 35
Median age, yr (range) 56 (25-74) 43 (22-73)
>60 yr, n (%) 15 (37) 3 (9)
Male sex, n (%) 24 (59) 21 (60)
Histological type, n (%)
N-TCL 35 (85) 20 (57)
PTCL-NOS 16 (39) 15 (43)
ALK-negative ALCL 14 (34) 4 (11)
AITL 5 (12) 1 (3)
EN-TCL 6 (15) 15 (43)
NK-TCL 4 (10) 9 (26)
HSTCL 0 (0) 1 (3)
SPTCL 1 (2) 2 (6)
EALT 1 (2) 3 (9)
Relapse sensitive 31 (76) 18 (51)
Relapse refractory 10 (24) 17 (49)
Transplantations before year 2000, n (%) 15 (37) 13 (37)
Median time to SCT, mo (range) 20 (7-113) 17 (2-135)
IPI score > 1 at SCT, n (%) 9 (22) 8 (23)
Elevated LDH at SCT, n (%) 11 (28) 11 (33)
Marrow þ at SCT, n (%) 1 (2) 6 (17)
Median prior chemotherapy regimens 2 3
Related/MUD/MM donor NA 19/9/7
EALT indicates enteropathy-associated TCL; MUD, matched unrelated; MM,
mismatched.
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uncontrolled active infection or symptomatic organ dysfunction.
From the mid-1990s to 2002, newly diagnosed TCL patients were
treated with alternating triple therapy with ASHAP (doxorubicin, methyl-
prednisolone, cytosine arabinoside, and cisplatin), MBACOS (bleomycin,
doxorubicin, cyclophosphamide, vincristine, methylprednisolone, and
methotrexate), andMINE (mesna, ifosfamide, mitoxantrone, and etoposide),
followed by ASCT [21]. In a subsequent trial, hyper-CVAD (hyperfractionated
cyclophosphamide, daunorubicin, vincristine, and dexamethasone, alter-
nating with methotrexate and cytarabine) was used as induction chemo-
therapy [21]. After 2002, patients were referred for transplantation if they
did not experience a complete remission after treatment with hyper-CVAD
or novel agents such as pralatrexate, romidepsin, and brentuximab. The
pattern of referral also depended on whether patients were treated by
physicians in the lymphoma department at our center or by those outside
MD Anderson (the latter group mainly received induction chemotherapy
with CHOP [cyclophosphamide, doxorubicin, vincristine, and prednisone]).
AlloSCT was reserved for patients with resistant or relapsed disease, if a
suitable donor was available.
All eligible patients had a biopsy-proven diagnosis of TCL, as determined
by histological and immunophenotypical analyses and deﬁned according to
the current classiﬁcation system at the time of biopsy. Possible diagnoses
were updated using the current version of the World Health Organization
classiﬁcation system. Patients with primary cutaneous TCL and ALK-positive
ALCL were excluded. Two patients with ALCL with unknown ALK status
were grouped with ALK-negative patients. The protocols and analysis were
approved by the MD Anderson institutional review board, and informed
consent was obtained from all patients. Standard deﬁnitions were used to
assess disease response [22]. The International Prognostic Index scores were
calculated according to published methods [19].
Statistical Analysis
The primary endpoints were overall survival (OS) and progression-free
survival (PFS) rates. Actuarial OS and PFS rates were estimated using the
Kaplan-Meier method. OS was estimated from the time of transplantation to
death or last follow-up, and PFS was estimated from the time of SCT to
disease progression, death, or last follow-up. Outcomes according to
transplantation type (alloSCT versus ASCT) were compared in univariate
analysis using Cox’s proportional hazards regression analysis. The compar-
isonwas stratiﬁed according to disease status at transplantation. Patient and
SCT characteristics were compared using chi-square and Fisher’s exact tests
for categorical variables and the Wilcoxon rank-sum test for continuous
variables. Statistical signiﬁcance was deﬁned at the .05 level, and all P values
were 2-sided. Statistical analyses were performed using STATA 9.0 software
(StataCorp, College Station, TX).
RESULTS
Patients
The study group was composed of 134 TCL patients: 88
ASCT and 46 alloSCT. Fifty-eight patients (43%) underwent
SCT (47 ASCT and 11 alloSCT) as frontline consolidation
therapy during their ﬁrst remission and 76 (57%) underwent
SCT (41 ASCT and 35 alloSCT) for relapsed disease. Patients’
pre-SCT characteristics and demographic data are summa-
rized in Tables 1 and 2.
The conditioning regimen consisted of BEAM (carmus-
tine, etoposide, cytarabine, and melphalan) or carmustine,
etoposide, cytarabine plus cyclophosphamide in 87% of ASCT
patients. The remaining patients received busulfan-
containing regimens. The conditioning regimens for alloSCT
varied in intensity. Thirteen patients (28%) underwent non-
myeloablative ﬂudarabine and cyclophosphamide condi-
tioning and 6 (13%) and 27 (59%) underwent melphalan and
ﬂudarabine and BEAM conditioning, respectively. Of the 46
alloSCT patients, 27 (59%) received transplants from human
histocompatible antigenematched siblings, 12 (26%) from
matched unrelated donors, and 7 (15%) from mismatched
donors.
Frontline SCT for TCL
Forty-seven patients underwent ASCT. AlloSCT was used
as a frontline strategy in 11 patients with a ﬁrst completeremission (CR1) or primary induction failure (PIF)/CR (n ¼
44) or with resistance to frontline conventional chemo-
therapy but a partial response (PR) to salvage treatment (PIF/
PR, n¼ 14). Patients’ characteristics are listed in Table 1. Most
patients (85% of ASCT and 91% of alloSCT) underwent
transplantations after year 2000. Peripheral TCL not other-
wise speciﬁed (PTCL-NOS) and angioimmunoblastic TCL
(AITL) were the dominant histological types in both the ASCT
(72%) and alloSCT (63%) groups. The median follow-up du-
rations among survivors in the ASCT and alloSCTgroupswere
35 months (range, 3 to 145) and 45 months (range, 9 to 90),
respectively. The 4-year OS and PFS rates for ASCT patients
were 76% (95% conﬁdence interval [CI], 56% to 88%) and 56%
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tistically signiﬁcantly different from the alloSCT group,
where the 4-year OS and PFS rates were 54% and 34%,
respectively.
Similar results were also observed for ASCT and alloSCT
when patients were grouped by CR1/PIF CR and PIF/PR. The
4-year OS rates for ASCT and alloSCT were 84% and 83%,
respectively (P ¼ .6) (Figure 1A). The 4-year PFS rates were
61% and 67% (P ¼ .8). Patients with PIF/PR had inferior out-
comes to those of the CR1/PIR CR patients. However, the
results were not statistically signiﬁcant between the ASCT
and alloSCT groups, where the 4-year OS rates were 44% and
20% (P ¼ .1) (Figure 1B), and the 4-year PFS rates were 33%
and 0% (P ¼ .08). We did not discern any differences in
outcome between the most common TCL subtypes included
(PTCL-NOS, AITL, and ALCL) (Figure 1C).SCT for Relapsed TCL
Seventy-six TCL patients underwent ASCT (n ¼ 41) and
alloSCT (n¼ 35). Patients’ characteristics are listed in Table 2.
Only 3% of alloSCT patients were older than 60 years
compared with 37% in the ASCT group (P < .05). The pro-
portion of patients with International Prognostic Index
score > 1, elevated lactate dehydrogenase, and refractory
disease (not responding to chemotherapy) before SCT was
not statistically different between the 2 groups. The 4-year
OS rates for ASCT and alloSCT were 50% and 36%, respec-
tively (P < .05). The 4-year PFS rate did not statistically
signiﬁcantly differ (38% and 28%) between the 2 groups.
Patients with relapsed sensitive disease experienced a ten-
dency toward a higher 4-year OS rate than did alloSCT pa-
tients (P ¼ .06) (Figure 2A) but not a higher PFS rate. The
same trends were observed when survival estimates were
compared according to disease status (CR2/3 versus PR) in
patients with relapse-sensitive disease. Those who were in
CR2/3 had a 4-year OS of 59% after ASCT and 53% after
alloSCT. Relapse-sensitive patients with a PR before SCT had
4-year OS rates of 55% and 22% after ASCT and alloSCT,
respectively.
Although inferior outcomes were observed after trans-
plantation in patients with relapsed and refractory TCL than
in those with chemosensitive disease, the results were not
statistically signiﬁcant between ASCT and alloSCT. The
corresponding 4-year OS estimates were 29% and 35%,
respectively (P ¼ .6) (Figure 2B) and the 4-year PFS rates 25%
and 18% (P ¼ .4). We were not able to discern statistically
signiﬁcant differences in OS in major histological types
included (Figure 3) or to detect any differences in outcome by
era of relapse (before or after the year 2000).Figure 1. (A) OS rates in TCL patients treated with ASCT or alloSCT during the CR1. (B)
after ASCT during the CR1, according to the most common histological types studiedGraft-versus-Lymphoma after AlloSCT in TCL
The conditioning regimens for alloSCT varied in intensity.
However, more patients were in CR1 or CR2/3 in the non-
myeloablative group (63%) than in the reduced-intensity
group (50%) (P ¼ .3). A graft-versus-lymphoma effect was
directly manifested by the responses to donor lymphocyte
infusion in 4 TCL patients with recurrent disease after
alloSCT: 2 PTCL, 1 AITL, and 1 subcutaneous panniculitis-like
TCL. These patients remained in continuous CR after 14þ,
36þ, 44þ, and 48þ months. We also observed a continuous
CR in 4 (2 ALCL and 2 PTCL) of 8 patients who underwent
alloSCT after not experiencing a durable response to ASCT.
These patients were last followed up at 12þ, 17þ, 21þ, and
216þ months after SCT. The graft-versus-lymphoma effect,
however, did not translate into improved survival, in part
because of increased toxicity in the alloSCT group. Indeed,
the 4-year nonrelapse mortality rate was signiﬁcantly higher
in alloSCT than in ASCT patients (40% and 17%, respectively;
P < .001).DISCUSSION
We previously reported encouraging results for TCL pa-
tients treatedwith ASCT [7]. This follow-up report represents
the largest single-institution study of ASCTand alloSCT in TCL
patients published to date. Although there is an inherent
selection bias in any retrospective study, we demonstrated a
4-year OS rate of 84% and PFS rate of 61% in TCL patients who
underwent ASCT as consolidation therapy after experiencing
a CR to conventional induction chemotherapy. Good results
were also observed after ASCT in relapsed-sensitive disease
of CR2/3 with a 4-year OS rate of 59%. Despite responses to
donor lymphocyte infusions in selected patients with
persistent low-volume disease after alloSCT, we found that
alloSCT resulted in no survival beneﬁts compared with ASCT
for patients with frontline or relapsed disease, after strati-
fying by level of response status before SCT. The histological
type of TCL was not associatedwith a signiﬁcant difference in
OS or PFS, thus conﬁrming the ﬁndings of other studies.
We acknowledge that our study has several limitations.
The time span of the transplantation covered 19 years.
However, about two thirds of patients underwent trans-
plantation after the year 2000. In addition, the proportion of
patients who underwent transplantation before or after
2000 was similar for both ASCT and alloSCT. OS and PFS were
measured from date of the transplantation rather than from
the date of ﬁrst treatment, as into other published clinical
trials. In addition, prognostic factors at the time of diagnosis
rather than at SCT are missing, because many patients were
diagnosed and underwent initial treatments outside MDOS rates in TCL patients treated with ASCT or alloSCT during PIF/PR. (C) OS rates
.
Figure 2. (A) OS rates after ASCT and alloSCT in patients with relapsed, chemosensitive TCL. (B) OS rates after ASCT and alloSCT in patients with relapsed, che-
morefractory TCL.
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the role of ASCT in TCL patients [7-12]. The OS rates in these
studies ranged from 50% to 70%. As in our study, chemo-
sensitivity and SCT in CR1 were important determinants of
outcome. A few prospective trials have also reported
encouraging results, with 3-year OS rates of 40% to 73% [9-
12]. In all studies, however, a signiﬁcant proportion of pa-
tients (25% to 59%) could not undergo SCT because of a poor
response to induction chemotherapy; this was an important
bias in studies that evaluated the role of SCT.
The role of SCT in relapsed disease is less controversial,
because it appears to be essential to improve survival rates. A
study reported a median OS duration of 5 months in patients
who were not eligible for an SCT procedure [23]. However,
the treatment of relapsed TCL remains challenging [24].
These unsatisfactory results for ASCT in TCL patients who do
not experience a pre-SCT CR and a response to donor
lymphocyte infusion provide a plausible rationale for using
alloSCT as a therapeutic modality. A comparative analysis in
our study did not reveal a superior outcome for alloSCT over
ASCT after adjusting for disease status (frontline versus
relapse) and prior response to conventional chemotherapy.
Similar ﬁndings were recently reported by the Center for
International Blood and Marrow Transplant Research
(CIBMTR) [17]. In that study, the outcomes in 115 patients
with different histological types of TCL were compared with
those in 126 patients who received an alloSCT, with noFigure 3. OS rates after ASCT in patients with relapsed, chemosensitive TCL
according to the most common histological types studied.statistical difference in OS or PFS. Unlike our study, however,
the CIBMTR report excluded patients who were older than
age 60. In addition, ALK-positive ALCL histological types were
included.
In conclusion, our results suggest that pre-SCT CR is
required for a good outcome after SCT in patients with TCL
and highlight the need for more effective induction chemo-
therapy for TCL patients. Considering the 84% 4-year OS rates
in CR1 patients and the unpredictable responses in patients
with relapsed disease, we favor the use of ASCT as consoli-
dation therapy after CR1. In our study, we could not establish
a superior outcome for alloSCT compared with ASCT for TCL
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